Skip to main content

Table 2 Correlation of HHLA2 expression with clinicopathological parameters in ovarian cancer

From: HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer

Variable Number of patients HHLA2 Expression
 +  P Value
Age
 ≥ 50 42 7 35 1.000
 < 50 22 4 18
Histological type
 Serous adenocarcinoma 50 8 42 0.940
 Others 14 3 11
Differentiation
 Poor 26 2 24 0.027
 Moderate 25 4 21
 Well 13 5 8
FIGO Stage
 I 9 3 6 0.160
 II 6 1 5
 III 36 6 30
 IV 13 1 12
Metastasis
 +  51 8 43 0.532
 − 13 3 10
Ascites
 +  11 1 10 0.732
 − 53 10 43
Vessel Invasion
 +  3 0 3 1.000
 − 61 11 50
Lymph Node
 +  8 2 6 0.900
 − 56 9 47
Platinum Sensitivity
 Platinum sensitive 50 8 42 0.940
 Platinum resistance 14 3 11
Relapse
 +  27 4 23 0.925
 − 37 7 30
Serum CA125 Before Surgery
 < 35 4 1 3 0.539
 ≥ 35 60 10 50
CA125
 +  37 5 32 0.148
 − 5 2 5
 Unknown 19 4 16
ER
 +  39 8 34 1.000
 − 17 3 15
 Unknown 4 0 4
PR
 +  33 6 29 1.000
 − 23 5 20
 Unknown 4 0 4
  1. Bold value indicates P < 0.05
  2. ER, Estrogen Receptor, PR Progesterone Receptor